RedHill signs Asian licensing agreement for migraine drug Rizaport

14 December 2016

Israel-based biopharmaceutical company RedHill Biopharma (TASE: RDHL) and Canada’s IntelGenx (OTCMKTS: IGXT) have signed an exclusive license agreement with Pharmatronic to commercialize the acute migraine treatment Rizaport in South Korea.

Under the agreement, RedHill grants Pharmatronic exclusive rights to the drug in South Korea, where Pharmatronic is based. Although financial terms of the deal were not disclosed, RedHill and IntelGenx, the latter of which provided the platform on which the drug is based, will receive an upfront payment, as well as additional milestone payments if the drug hits regulatory and commercial milestones, and sales royalties.

The agreement will run for an initial 10 years, with launch of the drug targeted for first-quarter 2019. The companies also intend to submit the Rizaport New Drug Application (NDA) to the US FDA in the first half of 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK